Research programme: ocular disorder therapeutics - KalVista/ Gadea Grupo Farmaceutico/University College Dublin/Universidad de Valladolid/RenaSci
Alternative Names: 3D-NETLatest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Gadea Grupo Farmaceutico; KalVista Pharmaceuticals; RenaSci; Universidad de Valladolid; University College Dublin
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Eye-disorders in Ireland
- 28 Jul 2018 No recent reports of development identified for research development in Eye-disorders in Spain
- 28 Jul 2018 No recent reports of development identified for research development in Eye-disorders in United Kingdom